About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets

by Medindia Content Team on July 12, 2006 at 8:29 AM
Font : A-A+

Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets

Aurobindo Pharma Ltd today said it has received tentative approval by USFDA for its anti-HIV drug, Didanosine chewable tablets of 100mg, 150mg and 200mg strengths.

This is the first generic version approval for Didanosine chewable in the world given by USFDA, Aurobindo Pharma informed the Bombay Stock Exchange.

Advertisement

The aforesaid product would now be available for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR), it added.

The company manufactures both Active Pharmaceutical Ingredients (API) and formulation for this generic version and with this approval, the antiretroviral (ARV) product portfolio of the company increased to 17.
Advertisement

Didanosine is a Nucleoside reverse transcriptase inhibitor (NRTI) class of drugs, and a key component of the ARV regimens in various parts of the world. This molecule enjoys approximately USD 100 mio of market share, it said.

The drug helps prevent AIDS virus from reproducing. It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is the version of VIDEX an anti-HIV medication manufactured by Bristol Myers Squibb.

The shares of the company was trading at Rs 608, up 2.16 per cent at the BSE.

Source:PTI News
Advertisement
Advertisement
open close
CONSULT ONLINE WITH A DOCTOR

×

Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests